efavirenz   Click here for help

GtoPdb Ligand ID: 11287

Synonyms: DMP-266 | DMP266 | EFV | L-743,726 | L-743726 | Stocrin® | Sustiva®
Approved drug PDB Ligand
efavirenz is an approved drug (FDA (1998), EMA (1999))
Compound class: Synthetic organic
Comment: Efavirenz is an antiviral drug that is used in the treatment of HIV. It is a synthetic non-nucleoside inhibitor (NNRTI) that binds to the HIV RNA-dependent DNA polymerase and thereby blocks viral DNA replication [6].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 38.33
Molecular weight 315.03
XLogP 4.63
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES FC([C@@]1(C#CC2CC2)OC(=O)Nc2c1cc(Cl)cc2)(F)F
Isomeric SMILES FC([C@@]1(C#CC2CC2)OC(=O)Nc2c1cc(Cl)cc2)(F)F
InChI InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
InChI Key XPOQHMRABVBWPR-ZDUSSCGKSA-N
Bioactivity Comments
Efavirenz is a substrate for cytochrome P450 enzymes and its modulation of CYP450 activity underlies potential for clinical drug interactions [3-4]. CYP2B6 is a major efavirenz catabolic enzyme [5] that catalyses generation of the inactive neurotoxic metabolite S-8-hydroxyefavirenz [1]. Interactions with other drugs that inhibit CYP2B6 increase efavirenz exposure.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CYP3A4 Hs Inhibitor Inhibition 4.8 pIC50 - 4
pIC50 4.8 (IC50 1.75x10-5 M) [4]
Description: Inhibition of CYP3A-mediated conversion of triazolam to 4-OH-triazolam in human liver microsomes.